Independent directory Public ClinicalTrials.gov records United States
Clear filters
ClinicalTrials.gov public records Last synced Sep 5, 2026, 8:25 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–20 of 20 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Conditions
Iron Deficiency Anaemia, Chronic Kidney Disease
Interventions
FCM (Ferric carboxymaltose) high ferritin target, FCM (Ferric carboxymaltose) low ferritin target, Oral Iron (Ferrous sulphate)
Drug
Lead sponsor
Vifor Pharma
Industry
Eligibility
18 Years and older
Enrollment
626 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2014
U.S. locations
1
States / cities
Wilmington, North Carolina
Conditions
Adenovirus, Anesthesia, Anxiety, Anxiolysis, Autism, Autistic Disorder, Bacterial Meningitis, Bacterial Septicemia, Benzodiazepine, Bipolar Disorder, Bone and Joint Infections, Central Nervous System Infections, Convulsions, Cytomegalovirus Retinitis, Early-onset Schizophrenia Spectrum Disorders, Epilepsy, General Anesthesia, Gynecologic Infections, Herpes Simplex Virus, Infantile Hemangioma, Infection, Inflammation, Inflammatory Conditions, Intra-abdominal Infections, Lower Respiratory Tract Infections, Migraines, Pain, Pneumonia, Schizophrenia, Sedation, Seizures, Skeletal Muscle Spasms, Skin and Skin-structure Infections, Treatment-resistant Schizophrenia, Urinary Tract Infections, Withdrawal, Sepsis, Gram-negative Infection, Bradycardia, Cardiac Arrest, Cardiac Arrhythmia, Staphylococcal Infections, Nosocomial Pneumonia, Neuromuscular Blockade, Methicillin Resistant Staphylococcus Aureus, Endocarditis, Neutropenia, Headache, Fibrinolytic Bleeding, Pulmonary Arterial Hypertension, CMV Retinitis, Hypertension, Chronic Kidney Diseases, Hyperaldosteronism, Hypokalemia, Heart Failure, Hemophilia, Heavy Menstrual Bleeding, Insomnia
Interventions
The POPS study is collecting PK data on children prescribed the following drugs of interest per standard of care:
Drug
Lead sponsor
Daniel Benjamin
Other
Eligibility
Up to 21 Years
Enrollment
3,520 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2019
U.S. locations
43
States / cities
Anchorage, Alaska • Little Rock, Arkansas • La Jolla, California + 37 more
Conditions
Healthy Subjects
Interventions
Fosfomycin
Drug
Lead sponsor
Vance Fowler, M.D.
Other
Eligibility
18 Years to 55 Years
Enrollment
19 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016
U.S. locations
1
States / cities
Chicago, Illinois
Completed Phase 1 Interventional Accepts healthy volunteers

4-way Crossover QT Evaluation in Healthy Subjects

NCT03709927
Conditions
Cardiac Repolarization in Healthy Subjects
Interventions
ZTI-01, Moxifloxacin 400mg, Placebo IV
Drug · Other
Lead sponsor
Nabriva Therapeutics AG
Industry
Eligibility
18 Years to 55 Years
Enrollment
41 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018
U.S. locations
1
States / cities
Baltimore, Maryland
Conditions
Pneumonia, Bacterial
Interventions
Amikacin fosfomycin inhalation solution, Aerosolized placebo
Drug
Lead sponsor
Cardeas Pharma
Industry
Eligibility
18 Years to 80 Years
Enrollment
143 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2016
U.S. locations
16
States / cities
Los Angeles, California • Gainesville, Florida • Jacksonville, Florida + 13 more
Conditions
Heart Failure, Heart Failure With Reduced Ejection Fraction (HFrEF), Heart Failure With Preserved Ejection Fraction (HFPEF), Iron Deficiency, Iron-deficiency Anemia (IDA)
Interventions
Ferric Carboxymaltose, Ferrous Sulfate
Drug
Lead sponsor
Syed Hamza Mufarrih
Other
Eligibility
18 Years to 100 Years
Enrollment
42 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
1
States / cities
Bowling Green, Kentucky
Conditions
Cystic Fibrosis
Interventions
FTI, AZLI, Placebo, AZLI
Drug
Lead sponsor
Gilead Sciences
Industry
Eligibility
18 Years and older
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
36
States / cities
Anchorage, Alaska • Phoenix, Arizona • Tucson, Arizona + 32 more
Conditions
Osteomyelitis
Interventions
oral antibiotics, intravenous antibiotics
Drug · Procedure
Lead sponsor
Julio Ramirez
Other
Eligibility
18 Years to 100 Years
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2018
U.S. locations
1
States / cities
Louisville, Kentucky
Conditions
Pediatric ALL
Interventions
ZTI-01 100 mg/kg, ZTI-01 75 mg/kg
Drug
Lead sponsor
Nabriva Therapeutics AG
Industry
Eligibility
Up to 11 Years
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2026
U.S. locations
5
States / cities
Orange, California • San Diego, California • Louisville, Kentucky + 2 more
Completed Not applicable Interventional Accepts healthy volunteers Results available

Single Dose Monurol for Treatment of Acute Cystitis

NCT00976963
Conditions
Urinary Tract Infection
Interventions
TMP/SMX, Fosfomycin
Drug
Lead sponsor
University of Washington
Other
Eligibility
18 Years to 45 Years · Female only
Enrollment
300 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2016
U.S. locations
1
States / cities
Seattle, Washington
Recruiting Phase 4 Interventional Accepts healthy volunteers

Use of Prophylactic Antibiotics Prior to OnabotulinumtoxinA

NCT05519072
Conditions
Antibiotic Prophylaxis
Interventions
Nitrofurantoin
Drug
Lead sponsor
Atlantic Health System
Other
Eligibility
18 Years and older · Female only
Enrollment
140 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2024
U.S. locations
1
States / cities
Morristown, New Jersey
Conditions
Healthy
Interventions
amikacin/fosfomycin
Drug
Lead sponsor
Cardeas Pharma
Industry
Eligibility
18 Years to 80 Years
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016
U.S. locations
1
States / cities
Minneapolis, Minnesota
Conditions
Urinary Tract Infection
Interventions
Fosfomycin tromethamine, Levofloxacin
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 99 Years
Enrollment
62 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
12
States / cities
Sylmar, California • Torrance, California • Decatur, Georgia + 9 more
Conditions
Pseudomonas Infection
Interventions
Fosfomycin tromethamine, Fosfomycin disodium
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 45 Years
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014
U.S. locations
1
States / cities
Overland Park, Kansas
Conditions
Coronavirus Infection (COVID-19), Pulmonary Arterial Hypertension, Urinary Tract Infections in Children, Hypertension, Pain, Hyperphosphatemia, Primary Hyperaldosteronism, Edema, Hypokalemia, Heart Failure, Hemophilia, Menorrhagia, Insomnia, Pneumonia, Skin Infection, Arrythmia, Asthma in Children, Bronchopulmonary Dysplasia, Adrenal Insufficiency, Fibrinolysis; Hemorrhage, Attention Deficit Hyperactivity Disorder, Multisystem Inflammatory Syndrome in Children (MIS-C), Kawasaki Disease, Coagulation Disorder, Down Syndrome
Interventions
The POP02 study is collecting bodily fluid samples (i.e., whole blood, effluent samples) of children prescribed the following drugs of interest per standard of care:
Drug
Lead sponsor
Duke University
Other
Eligibility
0 Years to 20 Years
Enrollment
5,000 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2026
U.S. locations
49
States / cities
Phoenix, Arizona • Little Rock, Arkansas • Los Angeles, California + 40 more
Conditions
Urinary Tract Infection (Diagnosis)
Interventions
Antibiotics
Drug
Lead sponsor
Megan Bradley
Other
Eligibility
65 Years and older · Female only
Enrollment
90 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Intravenous Fosfomycin Pharmacokinetics Study

NCT03910673
Conditions
Bacterial Infection, Multiple-drug Resistance, Pathogen Resistance
Interventions
Fosfomycin disodium
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 45 Years
Enrollment
39 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2020
U.S. locations
1
States / cities
Durham, North Carolina
Conditions
Urinary Tract Infections
Interventions
Antibiotic, Next Gen
Drug · Device
Lead sponsor
Wake Forest University Health Sciences
Other
Eligibility
18 Years to 80 Years · Female only
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2028
U.S. locations
1
States / cities
Winston-Salem, North Carolina
Conditions
Urinary Tract Infection Symptomatic, Acute Pyelonephritis, Urinary Tract Infection Complicated
Interventions
ZTI-01, Piperacillin-tazobactam
Drug
Lead sponsor
Nabriva Therapeutics AG
Industry
Eligibility
18 Years and older
Enrollment
465 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
6
States / cities
Pensacola, Florida • Augusta, Georgia • Columbus, Georgia + 3 more
Conditions
UTI
Interventions
Antibiotics
Drug
Lead sponsor
Megan Bradley
Other
Eligibility
65 Years and older · Female only
Enrollment
70 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania